Skip to content
Screener

Biogen BIIB Cash, Cash Equivalents, and Marketable Securities

Cash, Cash Equivalents, and Marketable Securities at other companies

CBIZ logo
CBIZCBZ
$45.05M+9.7%
Amalgamated Financial Corp. logo
Amalgamated Financial Corp.AMAL
$1.12B+35.1%
BILL Holdings logo
BILL HoldingsBILL
$459.54M+25.8%
Banner Corporation logo
Banner CorporationBANR
$1.67B-7.5%
Nektar Therapeutics logo
Nektar TherapeuticsNKTR
$694.16M+280%
Biohaven logo
BiohavenBHVN
$150.52M-32.9%

Other financials

Income statement

See full
Revenue$2.7B+3.4%
Gross profit$2.0B-4.0%
Operating income$610.7M
Net income$97.5M-84.6%
EPS (diluted)$0.66-84.8%

Balance sheet

See full
Cash & equivalents$1.3B-53.4%
Total debt$7.6B+14.6%
Total equity$18.8B+6.9%
Total assets$32.1B+13.3%

Cash flow

See full
Operating cash flow$448.9M+179%
CapEx$40.9M+53.8%
Free cash flow$408.0M+204%

Valuation

See full
Market cap$30.72B+63.7%
Enterprise value$36.99B+63.7%
P/E34.8×+22.5×
P/S3.1×+1.2×

Profitability

See full
Gross margin74%-1.4pp
Operating margin22.9%
Net margin8.8%-6.5pp
FCF margin26.9%+7.1pp

Returns & leverage

See full
Return on equity4.8%-4.3pp
Debt / equity0.4×0.0×
Current ratio1.9×-0.6×

Where this comes from

Reported directly by Biogen in its filing.

Tagged under the XBRL concept us-gaap:AvailableForSaleSecuritiesDebtSecurities.

The source filing: Biogen’s 10-Q, filed April 29, 2026.

Filed
Apr 29, 2026, 6:40 AM EDT
Fiscal quarter
Q1 FY2026
Calendar quarter
Q1 2026
Accession
0000875045-26-000045
(In millions)Amortized CostGross Unrealized GainsGross Unrealized LossesFair Value
Current482.6(0.1)482.5
Non-current64.864.8
Mortgage and other asset backed securities:
Non-current84.2(0.1)84.1
Total marketable debt securities$1,367.6$(2.0)$1,365.6
Marketable equity securities
Marketable equity securities, non-current$227.8$(90.4)$137.4
Total marketable equity securities$227.8$(90.4)$137.4

Item 1. Financial Statements (unaudited)

FAQ

What is Biogen's cash, cash equivalents, and marketable securities?
Biogen (BIIB) reported cash, cash equivalents, and marketable securities of $1.37B in Q1 2026.
What is the long-term trend for Biogen's cash, cash equivalents, and marketable securities?
Over 3 years (2020 to 2025), Biogen's cash, cash equivalents, and marketable securities has grown at a -15.5% compound annual growth rate (CAGR), from $2.05B to $1.24B.
What does cash, cash equivalents, and marketable securities mean?
This represents the most liquid assets held by the company, including cash on hand, bank deposits, and short-term investments that can be readily converted into cash. It serves as the primary buffer for operational liquidity and potential capital allocation activities. Investors monitor this to assess the company's ability to meet short-term obligations and fund growth initiatives.

Ask your AI about Biogen's cash, cash equivalents, and marketable securities.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude